„µ¦«¹„¬µ‡ªµ¤»„…°ŠÂ‡š¸Á¦¸¥š¸É„n°Ã¦‡ ĜŸ¼ožiª¥Ã¡¦Š°µ„µ«…oµŠ‹¤¼„°´„Á­ÂÁŒ¸¥¡¨´œÄœ
抡¥µµ¨¡¦³¤Š„»‘Á„¨oµ nªŠže 2545
Prevalence of Pathogenic Bacteria in Acute Maxillary Sinusitis at Phramongkutkloa
Hospital in Year 2002.
°£·µ˜ ­»ªµ­*, œª¡¦ «¦¸œª„»¨**, «»¨¸¡¦ ¡nªŠÂ¡**, ­»—µ¨´„¬–r Œ´œš¦´—µ*, ¥»¡µ Ÿ¨Ã£‡**,
„¦¸”µ ¤nªŠš°Š*, ­»¦Á— ‹µ¦»‹·œ—µ*, ¦µ¤ ¦´Š­·œ›»*r *
* „°ŠÃ­˜ œµ­·„ ¨µ¦·ŠŽrªš· ¥µÂ¨³‹»¨¸ªª·š¥µ‡¨·œ·‡,
** £µ‡‹»¨¸ªª·š¥µ ¨³£µ‡Áª«µ­˜¦rš®µ¦Â¨³»¤œ ª·š¥µ¨´¥Â¡š¥«µ­˜¦r¡¦³¤Š„»‘Á„¨oµ
š‡´—¥n°
ᦊ°µ„µ«…oµŠ‹¤¼„°´„Á­ ( Sinusitis ) Áž}œÃ¦‡¦³šµŠÁ—·œ®µ¥Ä‹š¸É¡Å—on°¥ ×¥
ÁŒ¡µ³š¸É¤¸­µÁ®˜»‹µ„ÁºÊ°Â‡š¸Á¦¸¥ Ž¹ÉŠÃ—¥ž„˜·Â¡š¥r¤„´ čo¥µš¸É°°„§š›·Í‡¦°‡¨»¤ÁºÊ°Â‡š¸Á¦¸¥š¸É
­¦oµŠÁ°œÅŽ¤r E - lactamase Ĝ„µ¦¦´„¬µ…´Êœ˜oœ šÎµÄ®oÁ„·—ž{®µ„µ¦­¼Á­¸¥‡nµÄo‹µn ¥Á„·œ‡ªµ¤Áž}œ
‹ÎµÁž}œ ¨³ °µ‹šÎµÄ®oÁ„·—ž{®µÁºÊ°—º°Ê ¥µÄœ£µ¥®¨´ŠÅ—o „µ¦ª·‹¥´ ‡¦´ÊŠœ¸Ê‹¹Š˜o°Š„µ¦«¹„¬µ‡ªµ¤»„
…°ŠÁºÊ°Â‡š¸Á¦¸¥„n°Ã¦‡ Sinusitis ¨³ „µ¦­¦oµŠÁ°œÅŽ¤r E - lactamase …°ŠÁºÊ°—´Š„¨nµª
ª·›¸„µ¦š—¨°Š: ×¥œÎµ­·ÉŠ­nŠ˜¦ª‹Ž¹ÉŠÁž}œ…°ŠÁ®¨ª‹µ„ᦊ°µ„µ«…oµŠ‹¤¼„…°ŠŸ¼ožiª¥ Sinusitis
ÁŒ¸¥¡¨´œ š¸Éŗo¦´„µ¦ª·œ·‹Œ´¥Ä®oŗo¦´ „µ¦Á‹µ³¨oµŠÃ¡¦Š°µ„µ«…oµŠ‹¤¼„ – „°ŠÃ­˜ «° œµ­·„
„¦¦¤ 抡¥µµ¨¡¦³¤Š„»‘Á„¨oµ ˜´ÊŠÂ˜n Á—º°œ ¤¸.‡.45 – ¡.‡.45 ‹Îµœªœ 20 ¦µ¥ ¤µšÎµ„µ¦Á¡µ³Â¥„
œ·—…°ŠÁºÊ°Â‡š¸Á¦¸¥š¸É„n°Ã¦‡ ¨³š—­°„µ¦­¦oµŠÁ°œÅŽ¤r E - lactamase …°ŠÁºÊ°š¸É¡Ã—¥ª·›¸
Chromogenic cephalosporin analog 87/312
Ÿ¨„µ¦ª·‹´¥: ¡ªnµ ˜´ª°¥nµŠš¸ÉÁ„ȝŗoš´ÊŠ®¤— 20 ¦µ¥ ¡ÁºÊ°„n°Ã¦‡ 19 ˜´ª š¸É¡¤µ„š¸É­»— ‡º°
Haemophilus influenzae ‹Îµœªœ 8 ¦µ¥ ‡·—Áž}œ 42.1 % ¦°Š¨Š¤µ ‡º° Klebsiella pneumoniae
‹Îµœªœ 3 ¦µ¥ ‡·—Áž}œ 15.79 % ¦°Š°´œ—´­µ¤ ‡º° Citrobacter sp. ‹Îµœªœ 2 ¦µ¥ ‡·—Áž}œ 10.5 %
¨³Å¤n¡ÁºÊ°Â‡š¸Á¦¸¥š¸ÉŤnčo°°„Ž·Á‹œÁ¨¥ œ°„‹µ„œ¸¥Ê ´Š¡ÁºÊ°š¸É­¦oµŠÁ°œÅŽ¤r E - lactamase 3
˜´ª ŗo„n H. influenzae , Moraxella catarrhalis ¨³ Staphylococcus aureus ‡·—Áž}œ 30 % …°Š
ÁºÊ°š¸Éš—­°„µ¦­¦oµŠÁ°œÅŽ¤r E - lactamase
„µ¦°£·ž¦µ¥Â¨³­¦»ž: ÁºÊ°š¸É­¦oµŠÁ°œÅŽ¤r E - lactamase 3 ˜´ª ŗo„n H. influenzae , Moraxella
catarrhalis ¨³ Staphylococcus aureus ‡·—Áž}œ 30 % …°ŠÁºÊ°š¸Éš—­°„µ¦­¦oµŠÁ°œÅŽ¤r E lactamase Áž°¦rÁŽœ˜r…°ŠÁºÊ°š¸ÉÂ¥„Å—o‡°n œ…oµŠ˜Éε ‹¹Š°µ‹Áž}œÂœªšµŠÄ®o¡š¥rÁ¨º°„čo¥µš¸É¤¸§š›·Í
°n°œ¨ŠÅ—o ˜n°¥nµŠÅ¦„Șµ¤ „µ¦ª·‹¥´ ‡¦´ÊŠœ¸­Ê ¦»žŸ¨‹µ„˜´ª°¥nµŠŸ¼ožiª¥Á¡¸¥Š 20 ¦µ¥Ášnµœ´Êœ Ž¹ÉŠ°µ‹œo°¥
Á„·œÅžÁœºÉ°Š‹µ„ …o°‹Îµ„´—Äœ„µ¦Á‹µ³¨oµŠÃ¡¦Š°µ„µ«…oµŠ‹¤¼„¤¸°¥¼n¤µ„ ¨³šÎµ„µ¦«¹„¬µÄœnªŠ§—¼
¦o°œ Ž¹ÉŠŸ¼ožiª¥¤´„Ťn¤¸°µ„µ¦¦»œÂ¦Š‹œ„¦³š´ÉŠ˜o°Š¤µ¡Â¡š¥r
Á°„­µ¦°oµŠ°·Š:
1. Erkan M, Aslan T, Ozcan M and Koq N. Bacteriology of antrum in adults with chronic
maxillary sinusitis. Laryngoscope 1994, 104 : 321-4.
2. Ramadan HH. What is the bacteriology of chronic sinusitis in adults? American Journal
of Otolaryngology 1995, 16 : 303-6.
3. Goldenhersh MJ, Rachelefsky GS, Dudley J, et al. The microbiology of chronic sinusitis
disease in children with respiratory allergy. J. Allergy Clin. Immunol 1990, 85 : 1030-9.
4. Brook I, Yocum P and Frazier EH. Bacteriology and E-lactamase activity in acute and
chronic maxillary sinusitis. Arch. Otolaryngol Head Neck Surg. 1996, 122 : 418-422.
5. Friedman R, Ackerman M, Wald E, et al. Ashma and bacterial sinusitisin children. J.
Allergy Clin. Immunol 1984, 74 : 185-9.
6. ­»£µª—¸ ž¦³‡»–®´Š­·˜, Œ´˜¦´¥ »ÁŒ·— ¨³­»¦¡¨ ŽºÉ°˜¦Š. ÁºÊ°Â‡š¸Á¦¸¥š¸ÉÁž}œ˜oœÁ®˜»Äœ
„µ¦°´„Á­ÁŒ¸¥¡¨´œ…°ŠÃ¡¦Š°µ„µ«…oµŠ‹¤¼„ – 抡¥µµ¨¦µ¤µ›·—¸. ¦µ¤µ›·—¸Áª­µ¦
2536, 16 : 323-29.
7. Jareoncharsri P, Bunnag C, Tunsuritawong P, et al. Bacteriology profile of acute and
chronic maxillary sinusitis. J. Infect. Dis. Antimicrob Agents 2001, 18 : 96-102.
8. ¡¸¦¡´œ›r Á‹¦·µ«¦¸. Ŏœ´­°´„Á­. Ĝ : °£·´¥ ª·ªµ«·¦·, Œª¸ª¦¦– »œœµ‡ .„. ˜Îµ¦µÃ¦‡®¼
‡° ‹¤¼„. „¦»ŠÁš¡¤®µœ‡¦ : 抡·¤¡rÁ¦º°œÂ„oª„µ¦¡·¤¡r, 2537 : 344-374.
9. ‡–·˜ ¤´œ˜µ£¦–r. „µ¦°´„Á­Á¦ºÊ°¦´Š…°ŠÃ¡¦Š°µ„µ«…oµŠ‹¤¼„. Ĝ : ­»£µª—¸ ž¦³‡»–®´Š­·˜,
»¼ „»¨ž¦³—·¬“µ¦¤–r .„. ˜Îµ¦µÃ­˜ œµ­·„ ¨µ¦·ŠŽrª·š¥µ, „¦»ŠÁš¡¤®µœ‡¦ : ¦·¬´š ñ
¨·­˜·‡¡´¨··ÉŠ ‹Îµ„´—, 2538 : 211-226.
10. ­»£µª—¸ ž¦³‡»–®´Š­·˜. „µ¦°´„Á­ÁŒ¸¥¡¨´œ…°ŠÃ¡¦Š°µ„µ«…oµŠ‹¤¼„. Ĝ : ˜Îµ¦µÃ­˜
œµ­·„ ¨µ¦·ŠŽrª·š¥µ. „¦»ŠÁš¡¤®µœ‡¦ : ¦·¬´šÃ±¨·­˜·‡¡´¨··ÉŠ ‹Îµ„´—, 2538 : 227-242.
11. Thielman NM and Neu HC. Bacterial cell wall inhibitors. In : Brody TM, Larner J and
Minneman KP. Eds. Human Pharmacology. Missouri : Mosby, 1998 : 655-666.
12. Koneman WE, Allen SD, Janda WM, et al. Introduction to Diacnostic Microbiology.
1sted. Philadelphia : J.B. Lippincott Company, 1994.
13. Leitch C and Boonlayangoor S. E-Lactamase tests. In : Isenberg HD. Ed. Clinical
Microbiology Procedures Handbook volume 1. Washinton DC : American Soceity for
Microbiology, 1992 : 5.3.1-5.3.7.
Abstract
Sinusitis is commonly found as a respiratory disease, especially caused by abcterial
infection. In initial treatment, a doctor usually prescribes anfibiotics that can affect all
of E-lactamase producing bacteria. However this practice is both a waste ful expense
and causes microorganisms to be resistant. In this study, we wanted to study the
prevalence of the pathogenic bacteria in sinusitis and E-lactamase producing bacteria.
Methods and Materials:
The specimens, fluid from the maxillary aspiration of 20 acute sinusitis patients at
Phramongkutklao hospital during March-April 2002, were sent to the microbiology
labolatory for aerobic and anaerobic culture. E-lactamase activity was determined by
the cephalosporin analog 87/312 method.
Result and Discussion;
In this study, 9 pathogenic bacteria were found from 20 specimens. The predominant
isolates were Haemophilus influenzae (8 isolates) about 42.1%, Klebsiella
pneumoniae (3 isolates) about 16.79% and Citrobacter sp. (2 isolates) about 10.5%
as well as anaerobic bacteria which was not found, We found 3 E-lactamaseproducing bacteria in about 30% of the determined bacteria, that were Haemophilus
influenzae, Moraxella catarrhalis and Staphylococcus aureus. This result is rather
low, therefore it may be a guideline for doctors to select a narrow-spectrum
antibiotic. However the conclusion of this study was determined from only 20
patients, which is a number because there were so many restrictions for aspiration and
this research was conducted during the summer time when patients usually have no
severe symtoms.